WBB Securities upgraded shares of Corium International, Inc. (NASDAQ:CORI) to a buy rating in a research report report published on Friday, The Fly reports.

Several other research firms have also recently issued reports on CORI. ValuEngine raised shares of Corium International from a sell rating to a hold rating in a research report on Friday, June 2nd. Zacks Investment Research raised shares of Corium International from a hold rating to a buy rating and set a $8.50 target price on the stock in a research report on Tuesday, June 6th. Cantor Fitzgerald reissued an overweight rating and issued a $12.00 target price (up from $10.00) on shares of Corium International in a research report on Friday, May 12th. Jefferies Group LLC set a $8.00 target price on shares of Corium International and gave the stock a buy rating in a research report on Thursday, April 20th. Finally, FBR & Co restated an outperform rating and issued a $13.00 price target (up previously from $12.00) on shares of Corium International in a report on Tuesday, April 18th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Corium International has an average rating of Buy and an average target price of $11.25.

Corium International (NASDAQ:CORI) traded up 4.94% during trading on Friday, reaching $9.14. 102,250 shares of the company’s stock traded hands. Corium International has a 1-year low of $2.67 and a 1-year high of $9.28. The firm’s market capitalization is $267.18 million. The firm has a 50 day moving average of $7.02 and a 200 day moving average of $4.78.

Corium International (NASDAQ:CORI) last released its earnings results on Thursday, May 11th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.05. Corium International had a negative return on equity of 1,550.00% and a negative net margin of 116.59%. The company had revenue of $7.35 million during the quarter, compared to analyst estimates of $6.05 million. Equities analysts forecast that Corium International will post ($1.69) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/07/12/corium-international-inc-cori-upgraded-at-wbb-securities.html.

In other news, major shareholder Perceptive Advisors Llc purchased 1,902,400 shares of Corium International stock in a transaction dated Thursday, May 25th. The stock was bought at an average price of $6.25 per share, with a total value of $11,890,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Life Sciences Maste Perceptive purchased 301,004 shares of Corium International stock in a transaction dated Friday, June 30th. The shares were purchased at an average cost of $7.71 per share, with a total value of $2,320,740.84. The disclosure for this purchase can be found here. Insiders own 45.70% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp increased its position in shares of Corium International by 118.1% in the first quarter. Bank of New York Mellon Corp now owns 25,269 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 13,683 shares during the period. Royce & Associates LP increased its position in shares of Corium International by 208.4% in the first quarter. Royce & Associates LP now owns 548,464 shares of the biopharmaceutical company’s stock valued at $2,293,000 after buying an additional 370,600 shares during the period. AWM Investment Company Inc. increased its position in shares of Corium International by 1,125.9% in the first quarter. AWM Investment Company Inc. now owns 2,451,700 shares of the biopharmaceutical company’s stock valued at $10,248,000 after buying an additional 2,251,700 shares during the period. Perceptive Advisors LLC purchased a new position in shares of Corium International during the first quarter valued at about $11,096,000. Finally, Broadfin Capital LLC increased its position in shares of Corium International by 45.2% in the first quarter. Broadfin Capital LLC now owns 2,787,121 shares of the biopharmaceutical company’s stock valued at $11,650,000 after buying an additional 867,400 shares during the period. 77.47% of the stock is owned by institutional investors.

Corium International Company Profile

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

The Fly

Analyst Recommendations for Corium International (NASDAQ:CORI)

Receive News & Stock Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related stocks with our FREE daily email newsletter.